Address book
Contacts
PATRIZIA PONTISSO
Position
Professoressa Ordinaria
Structure
Address
VIA GIUSTINIANI, 2 - PADOVA
Telephone
0498217872
1980: Graduation in Medicine and Surgery at the University of Padua. 1985: Specialization in Internal Medicine. 1988: Specialization in Clinical and Laboratory Haematology.
1989: Assistant Physician at the Medical Clinic II, University of Padua. 2006: Associate Professor of Internal Medicine at the Dept of Clinical and Experimental Medicine (from 2012 named Dept of Medicine), of the University of Padua. 2013: National Habilitation for Full Professor in Internal Medicine and in Gastroenterology.
2000-2001: member of the Editorial Board of the Italian Journal of Gastroenterology and Hepatology, now called Digestive and Liver Disease. 2008 -2011: Associate Editor of Digestive and Liver Disease.
1999: member of the Board of the Italian Association for the Study of the Liver (AISF). 2000-2002: National AISF Secretary.
2003-2013: Expert for the evaluation of educational events (CME) of the Ministry of Health.
2006-2015: member of the Scientific Board of the Interdepartmental Research Experimental Surgery, University of Padua; in October 2015 appointed Director of that Center.
MAIN LINES OF RESEARC: In the years 1983-1985 she has conducted research in molecular biology and characterization of novel recombinant vaccines at 'Pasteur Institute’ of Paris. She has standardized , among the first in Italy, a method for detection of HBV DNA in serum of HBV infected patients. In 1986 she spent a year of research aimed at the study of mechanisms of cellular infection by hepatitis B virus (HBV) at Rush University in Chicago. In 1993, in collaboration with the group of Prof. Baralle (ICGEB, Trieste) an original system for the characterization of HCV genotypes was developed which has allowed the identification of a new viral genotype (genotype 3). In 1994 the characterization of the receptor for the hepatitis B virus has led to the identification of a hepatic virus receptor, consisting in the serine protease inhibitor SerpinB3 (or SCCA1), a molecule that was later found involved in liver disease progression and cancer development. Since 2004, as leader of the Molecular Hepatology Group, she carried out research projects on mechanisms of carcinogenesis and development of new tumor markers for primary liver tumor. Within the laboratory activities, it is included the breeding of colonies of mice transgenic and knockout for SerpinB3.
CLINICAL ACTIVITY AND ORGANIZATION Prof. Pontisso conducts clinical activity at the Padua Teaching Hospital, Department of Medicine and is responsible for the Molecular Hepatology Laboratory (since 2004), where clinical and translational research activities are carrier out. She is also responsible for the Liver Biobank, approved by the local Ethics Committee (since 2007).
Member of the Board of the Department of Clinical and Experimental Medicine (2005-2007 and from October 2009 to 2011), Coordinator of the Scientific Committee (2007-2011), member of the Evaluation Committee (2007-2011), and of the Laboratory and Radiation Safety Committee (2007-2011 ) in the same Department. Member of the Research Committee of the Department of Medicine-DIMED (2012-2015).
SCIENTIFIC ACTIVITY Member of national and international research Associations, Prof. Pontisso is author of more than 280 full papers and 500 published abstracts. Total impact factor : 1911; Total citations: 8212; H-Index Total: 48
Currently she serves as a Referee for several peer-reviewed international journals
Notices
Teachings
- MEDICAL CLINIC 2, AA 2024 (MEP5071258)
- GENDER-SPECIFIC AND EVIDENCE-BASED CLINICAL APPROACH, AA 2024 (MEQ3104202)
- THE APPROACH TO PATIENTS, AA 2024 (MEP8085619)
- FIFTH YEAR PRACTICAL TRAINING, AA 2024 (MEQ0089719)
- MEDICAL CLINIC 1, AA 2023 (MEP5071231)
- OTHER LINGUISTIC ACTIVITIES, AA 2023 (MEP9086039)
- THE APPROACH TO PATIENTS, AA 2023 (MEP8085619)
- FIFTH YEAR PRACTICAL TRAINING, AA 2023 (MEP8085323)
- MEDICAL CLINIC 1, AA 2022 (MEP5071231)
- OTHER LINGUISTIC ACTIVITIES, AA 2022 (MEP9086039)
- THE APPROACH TO PATIENTS, AA 2022 (MEP8085619)
- FIFTH YEAR PRACTICAL TRAINING, AA 2022 (MEP8085323)
- MEDICAL CLINIC 1, AA 2021 (MEP5071231)
- OTHER LINGUISTIC ACTIVITIES, AA 2021 (MEP9086039)
- THE APPROACH TO PATIENTS, AA 2021 (MEP8085619)
- FIFTH YEAR CLINICAL INTERNSHIP, AA 2021 (MEQ1099219)
- MEDICAL CLINIC 1, AA 2020 (MEP5071231)
- OTHER LINGUISTIC ACTIVITIES, AA 2020 (MEP9086039)
- THE APPROACH TO PATIENTS, AA 2020 (MEP8085619)
- FIFTH YEAR CLINICAL TRAINING, AA 2020 (MEP9088559)
- INTERNSHIP, AA 2019 (MEP8085603)
- CLINICAL METHODOLOGY AND MEDICAL SEMIOTICS, AA 2019 (MEP5071058)
- OTHER LINGUISTIC ACTIVITIES, AA 2019 (MEP9086039)
- THE APPROACH TO PATIENTS, AA 2019 (MEP8085619)
- INTERNSHIP: MEDICAL AND SURGICAL SEMEIOTICS, AA 2019 (MEP5071057)
- CLINICAL METHODOLOGY AND MEDICAL SEMIOTICS, AA 2018 (MEP5071058)
- INTERNSHIP: MEDICAL AND SURGICAL SEMEIOTICS, AA 2018 (MEP5071057)
- CLINICAL METHODOLOGY AND MEDICAL SEMIOTICS, AA 2017 (MEP4069257)
- CLINICAL METHODOLOGY AND MEDICAL SEMIOTICS, AA 2017 (MEP4068425)
- CLINICAL METHODOLOGY AND MEDICAL SEMIOTICS, AA 2017 (MEP4069258)
- CURRICULUM PRACTICAL TRAINING OF INTERNAL MEDICINE (4TH YEAR), AA 2017 (MEP4067939)
- CLINICAL METHODOLOGY AND MEDICAL SEMIOTICS, AA 2016 (MEP3055459)
- CLINICAL METHODOLOGY AND MEDICAL SEMIOTICS, AA 2016 (MEP3055331)
- CURRICULUM PRACTICAL TRAINING OF INTERNAL MEDICINE (4TH YEAR), AA 2016 (MEO2047620)
- CURRICULUM PRACTICAL TRAINING OF MEDICAL SEMEIOTICS, AA 2016 (MEP4067938)
- CLINICAL METHODOLOGY AND MEDICAL SEMIOTICS, AA 2014 (MEP3055459)
- CLINICAL METHODOLOGY AND MEDICAL SEMIOTICS, AA 2014 (MEP3055331)
- CURRICULUM PRACTICAL TRAINING OF INTERNAL MEDICINE (4TH YEAR), AA 2014 (MEO2047620)
Research Area
In the years 1983-1985 she has conducted research in molecular biology and characterization of novel recombinant vaccines at 'Pasteur Institute’ of Paris. She has standardized , among the first in Italy, a method for detection of HBV DNA in serum of HBV infected patients. In 1986 she spent a year of research aimed at the study of mechanisms of cellular infection by hepatitis B virus (HBV) at Rush University in Chicago. In 1993, in collaboration with the group of Prof. Baralle (ICGEB, Trieste) an original system for the characterization of HCV genotypes was developed which has allowed the identification of a new viral genotype (genotype 3). In 1994 the characterization of the receptor for the hepatitis B virus has led to the identification of a hepatic virus receptor, consisting in the serine protease inhibitor SerpinB3 (or SCCA1), a molecule that was later found involved in liver disease progression and cancer development. Since 2004, as leader of the Molecular Hepatology Group, she carried out research projects on mechanisms of carcinogenesis and development of new tumor markers for primary liver tumor. Within the laboratory activities, it is included the breeding of colonies of mice transgenic and knockout for SerpinB3.
In the last years development of compounds against fibrosis progression and cancer is another field of translational research, togheter with regenerative medicine tools, based of molecular and cell biology techniques.
